A soft X-Ray Phase-Based Microscope for Biomedical Applications
用于生物医学应用的软 X 射线相位显微镜
基本信息
- 批准号:10606563
- 负责人:
- 金额:$ 52.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-15 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalArthritisBackBiologicalBiomedical ResearchBloodCancer CenterCardiovascular DiseasesCellsClinicalClinical ResearchComputer softwareDatabasesDisease ProgressionElementsEvaluationGenerationsHealthHistologyHourHydration statusImageImage AnalysisIndividualLightLight MicroscopeMacrophageMalignant NeoplasmsMemorial Sloan-Kettering Cancer CenterMethodsMicroscopeModelingMultimodal ImagingNeoplasm Circulating CellsOpticsOsteoporosisOutcomePathologistPenetrationPerformancePhasePreparationProceduresProcessRecommendationResearchResearch PersonnelResolutionRetrievalRoentgen RaysSamplingSchemeSliceSoftware ToolsSourceSpecimenStainsStructureSynchrotronsSystemTestingThickThinnessThree-Dimensional ImageThree-Dimensional ImagingTimeTissue SampleTissue imagingTissuesVisible RadiationX ray microscopyX-Ray Computed Tomographyabsorptionattenuationbiomedical imagingcell typecellular imagingcontrast imagingdata acquisitiondesignefficacy evaluationflexibilityimage processingimaging modalityimaging systemimprovedinnovationmetermicroscopic imagingmillimetermultimodalitynanonew technologyoptical imagingpreclinical studyprototypereconstructionsimulationsoft tissuesoftware developmentuser-friendly
项目摘要
Abstract
Biomedical images are typically obtained utilizing optical light or X-rays. Optical light is
suitable for thin tissue slices, but not suitable for obtaining quality 3D images of thick
tissue. Tissue specimens up to millimeter in thickness provide information about
structure, different cell types and their relationships. One of the problems with optical
imaging in thick tissue is the scattering of the optical light. X-rays can penetrate thick
tissue, but the currently commercially available X-ray microscope imaging systems, such
as the XRadia and Rigaku systems, are not optimal for soft tissue imaging. For the
Xradia Versa, the lowest energy X-ray spectrum is 30 kVp, which is too high for soft
tissue, while in the Xradia Ultra the field of view is only ~60 µm, and 3D imaging requires
several hours. In the case of the Rigaku system, absorption contrast is too low even at
low energies.
We propose to deliver an intensity-modulation phase-based soft X-ray microscope for
non-destructive synchrotron-quality imaging of intact biological samples with the
following features:
3D, quantitative and multimodal (phase, attenuation, scatter) images
Acquisition times more than 10 times shorter than in XRadia systems
Resolution of hundreds of nm, same as visible light microscopes
Field of view from 5 mm x 5 mm to 1 mm x 1 mm, resolution from 2 µm to less
than 0.5 µm
High-contrast images of cell composition
Imaging tissue/cells in their native hydrated state, with no staining and other
disrupting preparation procedures
Implementing two low energy X-ray sources: 5.4 keV and 8 keV. The user can
switch back and forth between the two options, as well as adjust the resolution
dynamically
This will be realized by combining intensity-modulation X-ray phase-based imaging (IM
XPBI) method with two innovations such as cycloidal CT acquisition and lab-based
ptychography.
The microscope will be installed at Memorial Sloan Kettering Cancer Center and
validated with a database of existing tissue samples. The 3D histology results from the
proposed microscope will be compared to histology results from conventional imaging
modalities to determine efficacy. Tests will also be carried out to study cancer-
associated cells in blood, such as circulating tumor cells and giant cancer-associated
macrophage-like cells discovered by Creatv MicroTech. Possibility to obtain high-
resolution high-contrast 3D images of cells in their native state will enhance our
biomedical research and clinical utility to cancer.
This novel technology will be helpful for basic, pre-clinical and clinical studies related to
many health conditions, such as cancer, osteoporosis, arthritis, cardiovascular disease
and will assist with understanding of how these diseases progress and how they can be
treated.
摘要
生物医学图像通常利用光学光或X射线获得。光是
适合薄组织切片,但不适合获得厚组织的优质3D图像
组织.厚度达毫米的组织标本提供了关于
结构,不同的细胞类型及其关系。光学的一个问题是
在厚组织中成像是光学光的散射。X射线可以穿透厚厚的
组织,但目前市售的X射线显微镜成像系统,如
由于XRadia和理学系统,不是软组织成像的最佳选择。为
Xradia Versa,最低能量X射线光谱为30 kVp,这对于软X射线来说太高了。
而Xradia Ultra的视场仅为~60 µm,3D成像需要
几个小时.在理学系统的情况下,吸收对比度太低,即使在
低能量。
我们建议提供一种基于强度调制相位的软X射线显微镜,
使用该方法对完整生物样品进行非破坏性同步加速器质量成像,
以下功能:
三维、定量和多模态(相位、衰减、散射)图像
采集时间比XRadia系统短10倍以上
分辨率可达数百nm,与可见光显微镜相同
视场从5 mm x 5 mm到1 mm x 1 mm,分辨率从2 µm到更小
小于0.5 µm
细胞组成的高对比度图像
·成像处于其天然水合状态的组织/细胞,没有染色和其他
中断准备程序
实现两个低能量X射线源:5.4 keV和8 keV。用户可以
在两个选项之间来回切换,以及调整分辨率
动态
这将通过结合强度调制X射线相位成像(IM)来实现
XPBI)方法,具有摆线CT采集和基于实验室的
重叠关系
该显微镜将安装在纪念斯隆凯特琳癌症中心,
用现有组织样本的数据库进行验证。3D组织学结果来自
建议的显微镜将与传统成像的组织学结果进行比较
以确定疗效的方式。还将进行癌症研究测试-
血液中的相关细胞,如循环肿瘤细胞和巨大的癌症相关细胞,
Creatv MicroTech发现的巨噬细胞样细胞。可能获得高-
高分辨率高对比度的3D图像的细胞在其自然状态将提高我们的研究。
用于癌症的生物医学研究和临床应用。
这项新技术将有助于基础,临床前和临床研究相关的
许多健康状况,如癌症、骨质疏松症、关节炎、心血管疾病
并将有助于了解这些疾病的进展以及它们如何被
治疗。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Technical note: Cartilage imaging with sub-cellular resolution using a laboratory-based phase-contrast x-ray microscope
- DOI:10.1002/mp.16599
- 发表时间:2023-07-11
- 期刊:
- 影响因子:3.8
- 作者:Esposito,Michela;Astolfo,Alberto;Olivo,Alessandro
- 通讯作者:Olivo,Alessandro
Freestanding high-aspect-ratio gold masks for low-energy, phase-based x-ray microscopy.
- DOI:10.1088/1361-6528/ac9b5f
- 发表时间:2022-11-07
- 期刊:
- 影响因子:3.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph David Ferrara其他文献
Joseph David Ferrara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph David Ferrara', 18)}}的其他基金
A soft X-Ray Phase-Based Microscope for Biomedical Applications
用于生物医学应用的软 X 射线相位显微镜
- 批准号:
10160910 - 财政年份:2020
- 资助金额:
$ 52.12万 - 项目类别:
A soft X-Ray Phase-Based Microscope for Biomedical Applications
用于生物医学应用的软 X 射线相位显微镜
- 批准号:
10376333 - 财政年份:2020
- 资助金额:
$ 52.12万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
$ 52.12万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 52.12万 - 项目类别:
Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
- 批准号:
10068495 - 财政年份:2024
- 资助金额:
$ 52.12万 - 项目类别:
Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 52.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
- 批准号:
24K19850 - 财政年份:2024
- 资助金额:
$ 52.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
$ 52.12万 - 项目类别:
Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
- 批准号:
489316 - 财政年份:2023
- 资助金额:
$ 52.12万 - 项目类别:
Operating Grants
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
- 批准号:
23K14987 - 财政年份:2023
- 资助金额:
$ 52.12万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
$ 52.12万 - 项目类别:
Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
- 批准号:
10733789 - 财政年份:2023
- 资助金额:
$ 52.12万 - 项目类别: